20
Oct

Investigational Immunotherapy Was Safe, Tolerable, and Showed Some Activity Against Melanoma

PHILADELPHIA — The investigational immunotherapeutic IMC-20D7S was safe, rx well tolerated, story and showed signs of modest clinical activity for patients with advanced melanoma, according to results from a first-in-human phase I clinical trial published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

“Even though immunotherapy has significantly improved outcomes for some patients with advanced melanoma, many patients have tumors that do not respond to currently available treatments or have tumors that initially respond but then become resistant to them,” said Jedd D. Wolchok, MD, PhD, the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation and chief of the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center (MSK) in New York. “In this study, we evaluated the safety and early clinical activity of a new antimelanoma immunotherapy.

Read Full Article Here >>